Loss of APAF-1 expression is associated with early recurrence in stage I, II, and III colorectal cancer
- 2 August 2016
- journal article
- research article
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 401 (8) , 1203-1210
Abstract
Purpose Apoptotic protease activating factor-1 (APAF-1) is a key regulator in the mitochondrial apoptotic pathway and an important diagnostic and therapeutic biomarker. Loss of APAF-1 expression has been observed in various tumors including colorectal cancer. The aim of our study was to evaluate the relationship between loss of APAF-1 expression and early recurrence of stage I–III colorectal cancer. Methods We investigated 165 out of 492 patients who had undergone curative resection for colorectal cancer between 1991 and 2001. Sixty-one patients (37.0 %) had early recurrence within 1 year after surgery. Tissue microarrays were used for immunohistochemical detection of APAF-1. Results The mean age of patients with recurrence was 58 years (range, 24–85); 88 (53.3 %, 88/165) were male. APAF-1 was expressed in 32 (19.4 %, 32/165) cases and was not expressed in 133 (80.6 %, 133/165). In univariate analysis, early recurrence significantly correlated with loss of APAF-1 expression (p = 0.017), tumor stage (p = 0.005), N category (p = 0.001), and lymphatic invasion (p = 0.008). In a logistic regression model, loss of APAF-1 expression (p = 0.015, 95 % CI = 1.280–10.063) and N category (p = 0.001, 95 % CI = 0.004–0.739) proved to be independent risk factors associated with early recurrence. In patients with lymph node metastasis, early recurrence was more frequent in the APAF-1-negative group than in the APAF-1-positive group (46.2 % (54/117) vs. 22.2 % (6/27), p = 0.023). Conclusions Loss of APAF-1 expression is associated with early recurrence in stage I–III colorectal cancer, suggesting that APAF-1 may have clinical value as a predictive marker of early recurrence.Keywords
This publication has 32 references indexed in Scilit:
- MicroRNAs predict and modulate responses to chemotherapy in colorectal cancerCell Proliferation, 2015
- Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1Current Protein & Peptide Science, 2015
- Computational Analysis of mRNA Expression Profiles Identifies MicroRNA-29a/c as Predictor of Colorectal Cancer Early RecurrencePLOS ONE, 2012
- MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapyThe International Journal of Biochemistry & Cell Biology, 2010
- Reduced Expression of Apaf-1 in Colorectal Adenocarcinoma Correlates with Tumor Progression and Aggressive PhenotypeAnnals of Surgical Oncology, 2007
- Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancerEuropean Journal of Cancer, 2007
- Reoperation for Recurrent Colorectal CancerClinics in Colon and Rectal Surgery, 2006
- Allelic Imbalance of 12q22–23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous MelanomaCancer Research, 2004
- Analysis of APAF‐1 expression in human cutaneous melanoma progressionExperimental Dermatology, 2004
- The preoperative assessment and postoperative surveillance of patients with colon and rectal cancerSurgical Clinics of North America, 2002